4536 — SANTEN PHARMACEUTICAL Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapHigh Flyer

Market Cap
¥558bn
Enterprise Value
¥537bn
Revenue
¥292bn

Annual income statement for SANTEN PHARMACEUTICAL, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	266,257	279,037	301,965	300,004	291,624
Cost of Revenue
Gross Profit	156,586	166,087	178,709	171,027	169,743
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	228,890	282,425	264,302	253,841	243,901
Operating Profit	37,367	-3,388	37,663	46,163	47,723
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	35,616	-5,799	29,874	47,481	47,442
Provision for Income Taxes
Net Income After Taxes	27,189	-14,983	26,703	35,853	37,561
Minority Interest
Net Income Before Extraordinary Items
Net Income	27,218	-14,948	26,643	36,256	37,369
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	27,218	-14,955	26,642	36,256	37,369
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	65.3	26.3	109	109	124
Dividends per Share